Summary

• Vitroscope has secured $5 million in seed investment and $2 million in non-dilutive funding from the Research Council of Norway.
• Its vitro.alive platform supports six independent experiments with controlled fluid flow, environmental monitoring, and live-cell imaging.
• The company plans customer testing of its 96-experiment vitro.scale system in 2027, ahead of commercial introduction targeted for 2028.

Norwegian biotechnology company Vitroscope has secured $7 million to expand laboratory equipment that keeps living human tissue under controlled conditions for extended experiments, supporting research into drug responses, immune activity, and disease mechanisms.

The Trondheim-based company raised $5 million in seed investment co-led by Cerberus Ventures and YZR Capital, alongside $2 million in non-dilutive funding from the Research Council of Norway. Arcas Ventures, Golden Egg Check, Devico Invest, and several individual investors participated in the equity round.

The financing will support commercial deployment of vitro.alive, Vitroscope’s existing benchtop research platform, and validation of vitro.scale, a higher-throughput instrument designed to accommodate 96 parallel experiments. Customer testing of the larger system is targeted for 2027, with commercial introduction planned for 2028.

Vitroscope has now secured $8.8 million in total funding. Its technology addresses a practical limitation of laboratory research: maintaining suitable conditions around living tissue while observing how biological processes develop over time.

Fluid movement changes the experimental environment

Researchers increasingly use human tissue samples and organoids to investigate biological processes and assess potential treatments. Organoids are three-dimensional structures grown from cells that reproduce selected characteristics of particular tissues or organs, allowing scientists to examine processes that may be difficult to study using conventional cell cultures.

However, the environment surrounding a sample can influence its behaviour. Living tissue needs suitable oxygen and nutrient supplies, while the accumulation of metabolic waste or changes in temperature can alter cellular activity.

Traditional laboratory plates provide a useful environment for many experiments, but static conditions do not necessarily reproduce the fluid movement experienced by tissue inside the body. More complex models may consequently become less viable or behave differently as an experiment progresses.

Vitroscope uses perfusion to address part of that problem, moving controlled amounts of fluid around or through biological material. Its equipment combines programmable flow with control of oxygen, pH, and temperature, allowing researchers to maintain selected experimental conditions while gathering observations.

The vitro.alive instrument supports six independent experiments and is designed to work with standard inverted microscopes. Researchers can therefore use existing imaging equipment to observe tissue samples under controlled flow rather than transferring every experiment to an entirely separate microscopy system.

Integrating the fluid-handling and environmental controls within one platform can also simplify the physical setup of experiments. The company provides software for setting protocols, monitoring conditions, and managing information collected during an experiment.

Those capabilities allow researchers to record changes repeatedly rather than relying only on a measurement taken at a fixed endpoint. A biological response may begin gradually, peak several hours after exposure to a treatment, or change direction as tissue adapts to its surroundings.

Repeated observations can help distinguish those patterns, although their scientific value depends on the quality of the tissue model and the measurements collected.

Seven-day experiments demonstrate early capabilities

Vitroscope has described experimental work involving several types of human tissue. In collaboration with Instant Bio, its technology maintained vascularised human brain organoids under perfusion for seven days.

The work demonstrates that a complex laboratory model can remain under controlled flow and observation over an extended period. However, it does not establish that every organoid or fresh tissue sample will remain viable for the same duration.

Different biological models have different requirements, and researchers must select conditions appropriate to the tissue and the process being investigated. The characteristics of a brain organoid cannot automatically be assumed to apply to liver or kidney models.

In separate work, primary human liver cells formed organised tissue structures on the platform under conditions that were not reproduced in standard well plates. Another study examined kidney cells lacking AdipoR1, a receptor associated with diabetic kidney disease, and identified differences in their responses to physiological fluid flow.

These examples show how environmental control can influence what researchers observe. They also indicate that fluid movement may form part of an experimental question rather than merely serving to keep samples supplied with nutrients.

The results remain laboratory findings. Human tissue models can reproduce selected biological characteristics, but they do not capture every interaction occurring in a complete human body.

For drug development, the predictive value of a model needs to be established against relevant biological and clinical evidence. Maintaining tissue for longer may provide additional information without guaranteeing that the resulting observations will predict treatment effects in patients.

Higher throughput introduces different requirements

Vitroscope’s next instrument, vitro.scale, is intended to increase capacity from six to 96 parallel experiments. That expansion would allow laboratories to investigate more samples, compounds, or experimental conditions during a comparable research programme.

Higher throughput can be useful when scientists need to compare responses across multiple tissue models or evaluate a larger group of potential treatments. However, running more experiments simultaneously also increases the importance of consistency.

Each experimental position needs suitable fluid handling and environmental control, while results must remain traceable to the relevant sample and procedure. Differences between positions can introduce variation that complicates comparisons.

Laboratories will therefore need to examine whether the larger system maintains the required conditions across its full operating capacity. Relevant evidence would include reproducibility, sensor performance, sample compatibility, and the consistency of results between experimental runs.

Vitroscope is targeting customer testing in 2027 before a planned commercial launch in 2028. Those dates represent development objectives rather than confirmation that the larger system has completed validation.

Customer trials should also establish how the instrument fits into existing laboratory operations. Research teams will need to consider sample preparation, equipment maintenance, consumables, data handling, and the training required to operate a more complex experimental programme.

Research adoption depends on useful data

Pharmaceutical companies and academic laboratories have growing interest in experimental methods that provide information relevant to human biology. More detailed tissue models may support decisions about which treatments deserve further investigation, particularly where conventional tests provide limited information.

Longitudinal measurements can also support computational research by providing observations of biological responses across time. Such datasets may be useful for developing and evaluating analytical models, including machine learning systems, provided they are sufficiently consistent and accurately labelled.

The ability to collect more information does not independently establish that every measurement contributes to better research decisions. Laboratories must determine which observations are relevant, whether the methods can be repeated, and how results compare with established approaches.

Regulators are also examining the appropriate use of human-relevant laboratory methods alongside conventional testing. Their acceptance depends on the purpose of a particular method and the evidence supporting its reliability, rather than a general presumption that one experimental technology can replace every existing test.

Vitroscope’s financing will support the transition from a commercially available six-experiment platform towards a larger system intended for more extensive research programmes. The next evidence of progress will come from customer validation of vitro.scale and wider laboratory experience with the existing instrument.

Those results will establish whether the company’s controlled-perfusion approach can deliver sufficiently consistent, useful biological information to become a routine part of pharmaceutical and research laboratory workflows.